share_log

Truist Financial Cuts Teleflex (NYSE:TFX) Price Target to $241.00

Truist Financial Cuts Teleflex (NYSE:TFX) Price Target to $241.00

Truist Financial將Teleflex(紐約證券交易所代碼:TFX)目標價下調至241.00美元
kopsource ·  2022/09/22 09:41

Teleflex (NYSE:TFX – Get Rating) had its target price dropped by investment analysts at Truist Financial from $265.00 to $241.00 in a report released on Thursday, The Fly reports. Truist Financial's price target points to a potential upside of 12.52% from the stock's current price.

據The Fly報道,在週四發佈的一份報告中,Truist Financial的投資分析師將Teleflex(紐約證券交易所代碼:TFX-GET評級)的目標價從265.00美元下調至241.00美元。Truist Financial的目標價顯示,該股較當前股價有12.52%的潛在上漲空間。

A number of other brokerages have also commented on TFX. Piper Sandler reduced their target price on shares of Teleflex from $295.00 to $265.00 in a research report on Thursday, July 28th. Wolfe Research assumed coverage on shares of Teleflex in a research report on Tuesday, July 5th. They set an "outperform" rating and a $300.00 target price on the stock. Wells Fargo & Company lowered shares of Teleflex from an "overweight" rating to an "equal weight" rating and set a $248.00 target price on the stock. in a research report on Friday, July 29th. Morgan Stanley dropped their price objective on shares of Teleflex from $300.00 to $278.00 and set an "equal weight" rating on the stock in a research note on Friday, July 29th. Finally, StockNews.com downgraded shares of Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, July 29th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average target price of $322.70.

其他一些券商也對TFX發表了評論。派珀·桑德勒在7月28日星期四的一份研究報告中將Teleflex的股票目標價從295.00美元下調至265.00美元。Wolfe Research在7月5日星期二的一份研究報告中對Teleflex的股票進行了報道。他們為該股設定了“跑贏大盤”的評級和300.00美元的目標價。富國銀行將Teleflex的股票評級從增持下調至持平,併為該股設定了248.00美元的目標價。在7月29日星期五的一份研究報告中。摩根士丹利在7月29日星期五的一份研究報告中將Teleflex的目標股價從300.00美元下調至278.00美元,並對該股設定了“同等權重”的評級。最後,在7月29日星期五的一份研究報告中,StockNews.com將Teleflex的股票評級從買入下調至持有。六位分析師對該股的評級為持有,五位分析師對該股的評級為買入。根據MarketBeat.com,該公司的平均評級為持有,平均目標價為322.70美元。

Get
到達
Teleflex
Teleflex
alerts:
警報:

Teleflex Trading Down 2.7 %

Teleflex交易下跌2.7%

Shares of Teleflex stock opened at $214.19 on Thursday. The company has a market capitalization of $10.05 billion, a P/E ratio of 19.91, a P/E/G ratio of 2.17 and a beta of 1.10. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.43 and a current ratio of 2.27. The company has a fifty day moving average of $242.25 and a 200 day moving average of $279.20. Teleflex has a fifty-two week low of $213.76 and a fifty-two week high of $391.39.

週四,Teleflex的股票開盤報214.19美元。該公司市值為100.5億美元,市盈率為19.91倍,市盈率為2.17倍,貝塔係數為1.10。該公司的負債權益比率為0.42,速動比率為1.43,流動比率為2.27。該公司的50日移動均線切入位在242.25美元,200日移動均線切入位在279.20美元。Teleflex的股價為213.76美元,為52周低點,52周高點為391.39美元。

Teleflex (NYSE:TFX – Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical technology company reported $3.39 EPS for the quarter, beating the consensus estimate of $3.34 by $0.05. Teleflex had a net margin of 18.16% and a return on equity of 16.84%. The business had revenue of $704.50 million during the quarter, compared to the consensus estimate of $719.50 million. During the same quarter in the prior year, the firm earned $3.35 EPS. The business's revenue was down 1.3% on a year-over-year basis. On average, sell-side analysts anticipate that Teleflex will post 13.13 earnings per share for the current fiscal year.
Teleflex(紐約證券交易所代碼:TFX-GET Rating)上一次發佈季度收益數據是在7月28日星期四。這家醫療技術公司公佈本季度每股收益為3.39美元,比普遍預期的3.34美元高出0.05美元。Teleflex的淨利潤率為18.16%,股本回報率為16.84%。該業務本季度的收入為7.045億美元,而普遍預期為7.195億美元。去年同期,該公司每股收益為3.35美元。該業務的收入同比下降了1.3%。賣方分析師平均預計Teleflex本財年每股收益將達到13.13美元。

Institutional Inflows and Outflows

機構資金流入和流出

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TFX. Inspire Investing LLC purchased a new stake in shares of Teleflex during the first quarter worth about $368,000. National Bank of Canada FI boosted its position in Teleflex by 7,726.3% during the first quarter. National Bank of Canada FI now owns 13,383 shares of the medical technology company's stock worth $4,633,000 after acquiring an additional 13,212 shares during the last quarter. Regentatlantic Capital LLC boosted its position in Teleflex by 2.3% during the first quarter. Regentatlantic Capital LLC now owns 2,215 shares of the medical technology company's stock worth $786,000 after acquiring an additional 50 shares during the last quarter. Procyon Advisors LLC boosted its position in Teleflex by 47.0% during the second quarter. Procyon Advisors LLC now owns 992 shares of the medical technology company's stock worth $244,000 after acquiring an additional 317 shares during the last quarter. Finally, Stanley Laman Group Ltd. boosted its position in Teleflex by 16.7% during the first quarter. Stanley Laman Group Ltd. now owns 8,940 shares of the medical technology company's stock worth $3,172,000 after acquiring an additional 1,282 shares during the last quarter. Hedge funds and other institutional investors own 95.91% of the company's stock.

一些機構投資者和對衝基金最近增持或減持了TFX的股份。Inspire Investment LLC在第一季度購買了Teleflex的新股,價值約36.8萬美元。加拿大國民銀行FI在第一季度將其在Teleflex的頭寸增加了7726.3%。加拿大國民銀行FI現在擁有這家醫療技術公司13,383股票,價值4,633,000美元,在上個季度額外購買了13,212股票。RegentAtlantic Capital LLC在第一季度將其在Teleflex的頭寸增加了2.3%。RegentAtlantic Capital LLC在上個季度增持了50股後,現在擁有2215股這家醫療技術公司的股票,價值78.6萬美元。Procyon Advisors LLC在第二季度將其在Teleflex的頭寸增加了47.0%。Procyon Advisors LLC在上個季度增持了317股後,現在擁有992股這家醫療技術公司的股票,價值24.4萬美元。最後,Stanley Laman Group Ltd.在第一季度將其在Teleflex的頭寸提高了16.7%。斯坦利·拉曼集團有限公司(Stanley Laman Group Ltd.)目前持有這家醫療技術公司8,940股股票,價值3,172,000美元,該公司在上個季度又收購了1,282股。對衝基金和其他機構投資者持有該公司95.91%的股票。

About Teleflex

關於Teleflex

(Get Rating)

(獲取評級)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Teleflex公司設計、開發、製造和供應一次性醫療設備,用於全球危重護理和外科應用中的常見診斷和治療程序。它提供血管通路產品,包括Arrow品牌的導管、導管導航和尖端定位系統,以及用於靜脈治療、測量血壓和通過單一穿刺點提取血液樣本的骨內通路系統。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Teleflex (TFX)
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • The Worst May be Over for Target, But is the Stock Safe to Buy?
  • Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
  • Two Fun Stocks The Insiders Are Buying
  • 免費獲取StockNews.com關於Teleflex的研究報告(TFX)
  • 這三大股利支付者也擁有強勁的價格增長
  • 天然氣價格繼續回升,這些股票應該會受益
  • 對塔吉特來説,最糟糕的時期可能已經過去,但這隻股票買起來安全嗎?
  • 這些液態天然氣股票準備好上行了嗎?
  • 內部人士正在買入的兩隻有趣的股票

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.

接收Teleflex Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Teleflex和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論